Ramez Nassef Eskander MD

PubMed

• TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial ...
  Ramez Eskander, Jung-Yun Lee, Mansoor Mirza, Domenica Lorusso, Helen Mackay
  Journal of the National Comprehensive Cancer Network. 2025-03-28
• Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.
  Ramez N Eskander, Michael W Sill, Lindsey Beffa, Richard G Moore, Joanie M Hope
  Nature Medicine. 2025-03-05
• Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types.
  David R Gandara, Neeraj Agarwal, Shilpa Gupta, Samuel J Klempner, Miles C Andrews
  Journal for Immunotherapy of Cancer. 2025-02-06

Journal Articles

• Immune Checkpoint Inhibition in the Treatment of Gynecologic Cancer  
  Kristen Anderson, Ramez N. Eskander, Current Obstetrics and Gynecology Reports, 1/14/2018
• Independent psychometric validation of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24)  
  Stukan, M, �Zalewski, K, �Mardas, M, D. Filarska, M Szajewski, A. Kmiec, P. Binkowska, M. Pietrzak-Stukan, M. Dudziak, J.P. Grabowski, RN Eskander, E. Greimel, European Journal of Cancer Care, 1/1/2017
• Practice Bulletin No174: Evaluation and Management of Adnexal Masses American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Gynecology  
  Eskander RN, Berman M, Keder L, Obstet Gynecol, 1/1/2016
• A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer  
  Minion LE, Bai J, Monk BJ, Robin Keller L, Ramez EN, Forde GK, Chan JK, Tewari KS, Gynecol Oncol, 1/1/2015
• Immunotherapy in endometrial cancer-an evolving therapeutic paradigm  
  Longoria TC, Eskander RN, Gynecologic Oncology Research and Practice, 1/1/2015
• Impact of chemotherapy-induced neutropenia on survival in patients with breast, ovarian and cervical cancer  
  Eskander RN, Tewari KS, Journal of Hematological Malignancies, 1/1/2012
• Incorporation of Anti-angiogenic Therapies in the Treatment of Epithelial Ovarian Cancer: Current Perspectives and Future Directions  
  Eskander RN, Di Saia PJ, Current Angiogenesis, 1/1/2012
• Adnexal Masses in Pediatric and Adolescent Females: A review of the literature  
  Eskander RN, Bristow RE, Curr Obstet Gynecol Rep, 1/1/2011
• Join now to see all

Books/Book Chapters

• Guide to Survivorship for Women Who Have Ovarian Cancer 
  Chapter: Adding quality to life. 
  Eskander RN, Anastasia PJEditors: Bristow RE, Cornelison TL, Montz FJ.Johns Hopkins University PressEdition 2nd,2015
• Altchek's Diagnosis and Management of Ovarian Disorders 
  Chapter: Chemotherapy of ovarian cancer. 
  Page 415 - 424Eskander RN, Di Saia PJEditors: Deligdisch L, Kase NG, Cohen CJ.Cambridge University PressEdition 3rd,2013
• Textbook of Uncommon Cancer 
  Chapter: Borderline tumors and other rare epithelial tumors of the ovary. 
  Page 497 - 506Eskander RN, Diaz-Montes TP, Vang R, Armstrong DK, Bristow REEditors: Raghavan D, Blanke C, Johnson DH, Moots PL, Reaman GH, Rose PG, Sekeres MA.John Wiley & Sons, Inc.Edition 4th,2012

Abstracts/Posters

• Analysis of the complex immune-cell milieu of tumors from patients treated with immunotherapy to better understand clinical response.
  Shumei Kato, Ryosuke Okamura, Mina Nikanjam, Ramez Eskander, Paul Fanta, Suzanna Lee, et al, Society for Immunotherapy of Cancer, Washington, DC, 1/1/2018
• ATHENA (GOG-3020/ENGOT-ov45): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study of Rucaparib + Nivolumab Following Front-Line Platinum-Based Chemotherapy i...
  Bradley J. Monk, Robert L. Coleman, Keiichi Fujiwara, Amit M. Oza, Shannon N. Westin, David M. O'Malley, Thomas J. Herzog, Frederik Marme, Ana Oaknin, Ramez N. Eskande..., 17th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), Kyoto, Japan, 1/1/2018
• Cost-effectiveness of maintenance therapy in advanced ovarian cancer: Paclitaxel, bevacizumab, niraparib, rucaparib, olaparib, and pembrolizumab.
  Wolford JE, Bai J, Minion LE, Keller R, Eskander RN, Chan JK, Monk BJ, Tewari KS, ASCO (American Society of Clinical Oncology) Annual Meeting, Chicago, IL, 1/1/2018
• A phase I dose-escalation of hyperthermic intraperitoneal chemotherapy (HIPED) with carboplatin for the frontline treatment of advanced ovarian cancer (NCT02199171).
  Randall LM, Gillen D, Krill LS, Liu FW, Pfaendler K, Chen WP, Eskander RN, Tewari KS, Bristow RE, ASCO (American Society of Clinical Oncology) Annual Meeting, Chicago, IL, 1/1/2018
• Comprehensive genomic characterization of small cell neuroendocrine carcinoma of the cervix.
  Eskander RN, Elvin J., Charo L., et al, SGO (Society of Gynecologic Oncology) Annual Meeting, New Orleans, LA, 1/1/2018
• The impact of body mass index (BMI) classification on the likelihood of lymphadenectomy at the time of hysterectomy for endometrial cancer.
  Longoria TC, Clair KH, Paraghamian S, Vu H. Eskander RN, Bristow RE, SGO (Society of Gynecologic Oncology) Annual Meeting, Washington, DC, 1/1/2017
• Postoperative complications and return of bowel function among patients with advanced stage ovarian cancer following rectosigmoid resection with reanastomosis.
  Sanders BE, Eskander RN, Laus K, et al, SGO (Society of Gynecologic Oncology) Annual Meeting, Washington, DC, 1/1/2017
• Overexpression of enhancer of zeste homolog 2 (EZH2) in endometrial carcinoma: evidence from an NRG Oncology/Gynecologic Oncology Group trial.
  Krill L, Ali S, Eskander RN, et al, AACR (American Association for Cancer Research) Annual Meeting, New Orleans, LA, 1/1/2016
• Inhibition of the Wnt pathway in ovarian cancer tumorigenesis.
  Krill L, Jandial D, Blair C, Ji T, Eskander RN, Yokoyama N, Bristow R, Randall L, WAGO (Western Association of Gynecologic Oncologists) Annual Meeting, Sedona, AZ, 1/1/2016
• The predictive value of preoperative thrombocytosis for postoperative infection in ovarian cancer patients.
  Longoria TC, Alldredge J, Sawyer B, Bristow R, Eskander RN, WAGO (Western Association of Gynecologic Oncologists) Annual Meeting, Sedona, AZ, 1/1/2016
• Perioperative transfusion as an independent risk factor for postoperative infection in Gynecologic Oncology patients.
  Longoria TC, Alldredge J, Clair K, Randall L, Eskander RN, WAGO (Western Association of Gynecologic Oncologists) Annual Meeting, Sedona, AZ, 1/1/2016
• Assessment of palliative care training in gynecologic oncology: a Gynecologic Oncology Fellows Research Network Study.
  Eskander RN, Osann K, Dickson EL, Holman LL, Rauh-Hain JA, Spoozak LA, Wu E, Fader AN, Tewari KS, 45th Annual Meeting on Women's Cancer, Society of Gynecologic Oncology, Tampa, FL, 1/1/2014
• Short term morbidity and mortality associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent/advanced stage ovarian cancer.
  Cripe JC, Tseng J, Eskander RN, Thompson S, Fader AN, Tanner EJ, Bristow RE, 45th Annual Meeting on Women's Cancer, Society of Gynecologic Oncology, Tampa, FL, 1/1/2014
• Gynecologic Oncology fellow perspectives on research and career development symposia: a Gynecologic Oncology Fellows' and Allied Health Professionals' Research Network...
  Dickson EL, Lin JL, Tergas AI, Eskander RN, Mueller JJ, Holman LL, Bristow RE, Fader AN, 45th Annual Meeting on Women's Cancer, Society of Gynecologic Oncology, Tampa, FL, 1/1/2014
• Pilot study of the PARO Therapeutic Robotic demonstrates decreased pain, fatigue, and anxiety among patients with recurrent ovarian carcinoma.
  Eskander RN, Tewari KS, Osann K, Shibata T, 44th Annual Meeting on Women's Cancer, Society of Gynecologic Oncology, Los Angeles, CA, 1/1/2013
• Patients with microscopic residual disease experience decreased survival when time from surgery to initiation of chemotherapy exceeds 25 days: A Gynecologic Oncology G...
  Eskander RN, Java JJ, Tewari KS, Burger RA, Monk BJ, 44th Annual Meeting on Women's Cancer, Society of Gynecologic Oncology, Los Angeles, CA, 1/1/2013
• Beta Blocker use and Ovarian Cancer Survival: A retrospective cohort study.
  Eskander R, Bessonova L, Chui C, Ward K, Anton Culver H, Harrison T, Randall L, 43th Annual Meeting on Women's Cancer, Society of Gynecologic Oncology, Austin, TX, 1/1/2012
• Expression Patterns of the Wnt Pathway Inhibitors Dickkopf-3 (Dkk3) and Secreted Frizzled-Related Proteins (sFRP) 1 and 4 in Endometrial Endometrioid Adenocarcinoma: A...
  Eskander RN, Ali S, Lankes H, Dellinger T, Hoang B, Ramirez N, Monk B, Walker J, Eisenhauer E, Randall L, Gynecol Oncol, 43rd Annual Meeting on Women's Cancer-Society of Gynecologic Oncology, Austin, TX, 1/1/2012
• Flavokawain B (FKB), A novel naturally occurring chalcone, exhibits robust apoptotic effects in the treatment of a uterine leiomyosarcoma cell line.
  Eskander R, Randall L, Sakai T, Guo Y, Hoang B, Zi X, 2011 Annual WAGO (Western Association of Gynecologic Oncologists) Meeting, Park City, UT, 1/1/2011
• Flavokawain B, a kava chalcone, induces apoptosis in synovial sarcoma cell lines.
  Sakai T, Guo Y, Eskander R, Mefford J, Hopkins J, Zi X, Bhatia NN, Hoang, BH, 102nd AACR (American Association for Cancer Research) Annual Clinical Meeting, Orlando, FL, 1/1/2011
• DKK3, a secreted Wnt antagonist, suppress tumorigenic potential and lung metastasis of osteosarcoma.
  Guo Y, Rubin E, Pourmorady J, Christ S, Rooney K, Eskander R, Sakai T, Bhatia NN, Zi X, Hoang BH, 102nd AACR (American Association for Cancer Research) Annual Clinical Meeting, Orlando, FL, 1/1/2011
• Sonographic Findings Associated with the Diagnosis of Invasive Placentation.
  Tache V, Eskander R, Ramos G, Benirschke K, Romine L, Moore T, American Journal of Obstetrics and Gynecology, 2010 SMFM Annual Clinical Meeting, Chicago, IL, 1/1/2010
• The Influence of Gestational age on Urgent Delivery in Patients With Placenta Accreta-Experience with 100 Consecutive Cases.
  Eskander R, Warshak C, Moore TR, Resnik R, American Journal of Obstetrics and Gynecology, 2009 SMFM Annual Clinical Meeting, San Diego, CA, 1/1/2009
• Prenatal vs. Intraoperative Diagnosis of Placenta Accreta: Effects on Maternal Outcomes in 100 Consecutive Cases.
  Eskander R, Warshak C, Moore TR, Resnik R, American Journal of Obstetrics and Gynecology, 2009 SMFM Annual Clinical Meeting, San Diego, CA, 1/1/2009
• Management Experience with 82 consecutive Cases of Placenta Accreta.
  Warshak C, Eskander R, Resnik R, 2006 ACOG (American College of Obstetricians and Gynecologists) Annual Clinical Meeting, Washington, DC, 1/1/2006
• Join now to see all

Lectures

• Epigenetic Modifiers As a Therapeutic Approach in Gynecologic Cancers 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
• Ovarian Cancer: Emerging therapeutic Paradigms. 
  Cedars Sinai Medical Center, CA - 1/1/2018
• Management of Immune Checkpoint Inhibitor (ICPi) related toxicities: A new...but common frontier. 
  New Orleans, LA - 1/1/2018
• Epigenetic modifiers as a therapeutic approach in gynecologic cancers. 
  Chicago, IL - 1/1/2018
• Deteccion y prevencion del cancer de ovaries & Nuevos tratamientos para el cancer hereditario. 
  San Diego, CA - 1/1/2018
• Implications of opportunistic salpingectomy. The state of the science. 
  1/1/2018
• Pre-operative preparation & Post-operative care. 
  1/19/2017
• UCSD Division of Gynecologic Oncology-Updates in Practice. 
  1/3/2017
• Opportunistic Salpingectomy: Implications for ovarian cancer risk reduction. 
  1/1/2016
• Patient Selection and Perioperative Care. 
  1/1/2016
• Oncology Hot Topics-Care of the Patient with Ovarian Cancer 
  UC Irvine Medical Center - 1/26/2015
• Correlation between surgeon's assessment of residual disease and findings on post operative pre treatment computed tomography scan in women with advanced stage ovarian... 
  Chicago, IL - 1/1/2015
• Immunotherapy in Gynecologic Cancer: Intersection of the Mutanome and Genome. 
  1/1/2015
• Synthetic lethality in ovarian cancer: The novel paradigm of PARP inhibition. 
  1/1/2015
• Robotic Surgery: Where are we now? 
  1/1/2015
• Development and Evolution of Ovarian Cancer Therapeutics. 
  1/1/2015
• Ovarian Cancer: Where are we now? A review of recent advances in screening, diagnosis and treatment. 
  1/1/2015
• Anti-angiogenesis therapy in ovarian cancer: The alpha and the omega. 
  1/1/2014
• Hospital readmission (30-day) following surgery for advanced stage ovarian cancer: analysis of risk factors and cost using the SEER-Medicare database. 
  Tampa, FL - 1/1/2014
• Gynecologic Cancers: Cervical Cancer Screening. 
  1/1/2014
• Gynecologic Cancers: Prevention and Screening. 
  1/1/2014
• Obstetrical hemorrhage and cesarean hysterectomy. 
  1/1/2014
• Negative survival impact associated with > 25 day interval from surgical cytoreduction to initiation of systemic therapy in advanced ovarian carcinoma: A Gynecologi... 
  Los Angeles, CA - 1/1/2013
• ASCO (American Society of Clinical Oncology) Update 2013. 
  1/1/2013
• Impact of Chemotherapy Induced Neutropenia on Survival in Patients with Solid Malignancies. 
  1/1/2012
• Join now to see all

Other

• The epigenetic landscape in the treatment of gynecologic malignancies. 
  Eskander RN, ASCO Educational Book
  1/23/2018
• Expert Opinion on the PORTEC-3 clinical trial. 
  Eskander RN, Medicine Matters Oncology
  https://oncology.medicinematters.com/expert-comment/15515530
  1/1/2018